Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313366 | 1.00 | CNR2 (0.43) | CNR2RAB9ANPC1FKBP1ABDKRB1 | |
| SCHEMBL2833638 | 0.96 | CNR2 (0.46) | CNR2RAB9ANPC1BDKRB1HTR7 | |
| SCHEMBL2833643 | 0.96 | CNR2 (0.46) | CNR2RAB9ANPC1BDKRB1HTR7 | |
| SCHEMBL10246104 | 0.90 | NPC1 (0.43) | RAB9ANPC1FKBP1ABDKRB1HTR7 | |
| SCHEMBL2934286 | 0.89 | HTR7 (0.40) | RAB9ANPC1FKBP1AHTR7TMEM97 | |
| SCHEMBL639859 | 0.88 | NPC1 (0.42) | RAB9ANPC1FKBP1ABDKRB1HTR7 | |
| SCHEMBL640463 | 0.88 | RAB9A (0.41) | RAB9ANPC1FKBP1AHTR7TMEM97 | |
| SCHEMBL4399065 | 0.87 | EBP (0.49) | CNR2NPC1 | |
| SCHEMBL13649888 | 0.86 | PSEN1 (0.53) | RAB9ANPC1HTR7TMEM97SIGMAR1 | |
| SCHEMBL3446456 | 0.86 | RAB9A (0.43) | RAB9ANPC1FKBP1ABDKRB1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229394-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-09-22 | — | — | EP | claimed |
| WO-2009090055-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-07-23 | — | — | WO | claimed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8278319-B2 | Substituted spiroamine compounds | GRUENENTHAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2009124746-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124734-A2 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| WO-2009115257-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009109364-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-11 | — | — | WO | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| WO-2008125570-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | CNR2 481/4885RAB9A 2485/4885NPC1 2399/4885 |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | RPS4X, RPS4Y1, CACNA1A | CNR2 348/4885RAB9A 948/4885NPC1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.